Table 1.
Characteristics and Antirheumatic Medication Among Patients With Sepsis Having RA.
| Characteristics | Result |
|---|---|
| ACPA positivity (%) | 19 (38.8) |
| RF positivity (%) | 32 (65.3) |
| ANA positivity (%) | 6 (12.2) |
| Medication, n (%) | |
| csDMARDs | 21 (42.9) |
| bDMARD | 7 (14.3) |
| Glucocorticoid monotherapy | 15 (30.6) |
| csDMARDs, n (%) | |
| Methotrexate | 17 (34.7) |
| Leflunomide | 1 (2.0) |
| Sulfasalazine | 1 (2.0) |
| Hydroxychloroquine | 2 (4.1) |
| bDMARDs, n (%) | |
| Adalimumab | 1 (14.3) |
| Etanercept | 1 (14.3) |
| Abatacept | 1 (14.3) |
| Rituximab | 3 (42.9) |
| Tocilizumab | 1 (14.3) |
Abbreviations: ACPA, anticitrullinated proteins/peptides antibodies; ANA, antinuclear antibodies; bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; RF, rheumatoid factor; TNF, tumor necrosis factor; RA, rheumatoid arthritis.